Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Best and Worst ETFs of 2011

By Ben Steverman - 2011-12-20T03:31:39Z

Photograph by JB Reed/Bloomberg

3 of 23

IShares Dow Jones U.S. Pharmaceuticals Index Fund

Total return: 16.3%

Fund company: BlackRock Fund Advisors

Industry focus: Health & biotechnology

Fund ticker/Total assets: IHE, $281 million

Top holdings, with 2011 total return:

Pfizer (PFE), +18%

Johnson & Johnson (JNJ), +6.4%

Merck & Co. (MRK), +1.95

According to a Dec. 19 report by Bloomberg Industries, the stocks of drugmakers should continue to outperform in 2012 because of their "defensive nature" amid "expectations of European recession and weak U.S. growth."